|
St group
(n=57) |
n-St group
(n=46) |
p value
|
Age (years), median ± IQR |
64.98±7.74 |
66.65±8.65 |
0.26 |
Gender, male; n (%) |
48 (85.7) |
34 (74.5) |
0.076 |
Cholesterol levels (mg/dl), median ± IQR |
134.46±48.01 |
139.89±36 |
0.18 |
Diabetes, n (%) |
13 (23.2) |
15 (32) |
0.22 |
Previous MI, n (%) |
29 (51.8) |
30 (63.8) |
0.15 |
Smoke habit, n (%) |
33 (58.9) |
23 (48.9) |
0.21 |
Familiy history of CAD, n (%) |
20 (35.7) |
7 (14.9) |
0.014 |
Hypertension, n (%) |
46 (82.1) |
39 (83) |
0.56 |
Three-vessels disease, n (%) |
47 (84) |
39 (83) |
0.55 |
Cerebrovascular disease, n (%) |
4 (7.1) |
2 (4.3) |
0.43 |
Pulmunary disease, n (%) |
9 (16.1) |
7 (14.9) |
0.55 |
Renal failure, n (%) |
1 (1.8) |
1 (2.1) |
0.7 |
EuroSCORE, median ± IQR |
3.35 (1.33-39) |
3.14 (1.21-37) |
0.571 |
β-blockers, n (%) |
50 (87) |
38 (83) |
0.62 |
ACE-Is, n (%) |
51 (90) |
41 (89) |
0.85 |
ARBs, n (%) |
13 (23) |
14 (32) |
0.22 |
Aspirin, n (%) |
54 (95) |
44 (96) |
0.81 |
IQR= interquartile range; n= number.
ACE-I = angiotensin converting enzyme inhibitor;
ARB= angiotensin receptor blocker. |